You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

Claims for Patent: 10,576,156

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,576,156

Title:	Compositions for drug administration
Abstract:	The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
Inventor(s):	Maggio Edward T.
Assignee:	Aegis Therapeutics, LLC
Application Number:	US15890131
Patent Claims:	1. An intranasal pharmaceutical composition comprising:a) epinephrine; andb) between about 0.05% and 0.5% (w/v) of an alkylglycoside;wherein the alkylglycoside is dodecyl-beta-D-maltoside,wherein the composition is an aqueous solution formulated for intranasal delivery to a subject, and provides systemic absorption of epinephrine upon delivery to the subject, andwherein the composition has a pH of about 2.0 to 5.0.2. The pharmaceutical composition of claim 1 , wherein the intranasal pharmaceutical composition further comprises citric acid claim 1 , sodium citrate claim 1 , propylene glycol claim 1 , glycerin claim 1 , ascorbic acid claim 1 , sodium metabisulfite claim 1 , ethylenediaminetetraacetic acid (EDTA) disodium claim 1 , benzalkonium chloride claim 1 , sodium hydroxide claim 1 , or a combination thereof.3. The pharmaceutical composition of claim 1 , wherein the intranasal pharmaceutical composition further comprises benzalkonium chloride claim 1 , ethylenediaminetetraacetic acid (EDTA) claim 1 , or a combination thereof.4. The pharmaceutical composition of claim 1 , wherein the composition provides a Cmax for the epinephrine in the subject that is about 2 fold or greater as compared to administration without the alkylglycoside.5. The pharmaceutical composition of claim 1 , wherein the composition provides a Tmax for the epinephrine in the subject that is about 2 fold or less as compared to administration without the alkylglycoside.6. The pharmaceutical composition of claim 1 , wherein the composition provides a Tmax for the epinephrine of about 0.3 hours or less in the subject.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.